LAWSUITS NEWS & LEGAL INFORMATION
Janssen Pharmaceuticals Reaches $181M Risperdal Settlement
This is a settlement for the Risperdal lawsuit.
Titusville, NJ: Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has reached a settlement and consent decree with 36 states and the District of Columbia regarding previously disclosed allegations related to promotional and marketing practices for its atypical antipsychotic prescription medication RISPERDAL®.
The company will pay approximately $181 million, an amount which has been previously accrued, as part of a consent decree to resolve state consumer protection law claims in the 36 states and the District of Columbia related to this matter. A designated portion of the total amount will be paid to each state participating in the settlement.
As part of the settlement, Janssen reaffirmed it would not promote any of its atypical antipsychotics for off-label uses or make any false or misleading claims related to those products.
In addition to the District of Columbia, the 36 states participating in the settlement are: Alabama, Arizona, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.
This multi-state consumer fraud settlement is separate and distinct from the recent disclosure made by Johnson & Johnson concerning an agreement in principle with the Department of Justice (DOJ) to settle three civil False Claims Act matters that are pending in U.S. courts: the sales and marketing of RISPERDAL® and INVEGA®; the sales and marketing of NATRECOR®; and allegations that Omnicare, Inc. was provided with rebates and other payments regarding RISPERDAL® and other products. With this agreement in principle with the DOJ, issues remain open that must be resolved before they can be finalized.
Published on Sep-3-12
The company will pay approximately $181 million, an amount which has been previously accrued, as part of a consent decree to resolve state consumer protection law claims in the 36 states and the District of Columbia related to this matter. A designated portion of the total amount will be paid to each state participating in the settlement.
As part of the settlement, Janssen reaffirmed it would not promote any of its atypical antipsychotics for off-label uses or make any false or misleading claims related to those products.
In addition to the District of Columbia, the 36 states participating in the settlement are: Alabama, Arizona, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.
This multi-state consumer fraud settlement is separate and distinct from the recent disclosure made by Johnson & Johnson concerning an agreement in principle with the Department of Justice (DOJ) to settle three civil False Claims Act matters that are pending in U.S. courts: the sales and marketing of RISPERDAL® and INVEGA®; the sales and marketing of NATRECOR®; and allegations that Omnicare, Inc. was provided with rebates and other payments regarding RISPERDAL® and other products. With this agreement in principle with the DOJ, issues remain open that must be resolved before they can be finalized.
Legal Help
If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form.Published on Sep-3-12
READ MORE Consumer Fraud Settlements and Legal News
READ MORE Drugs/Medical Settlements and Legal News